ReviewFrontiers in oncology2026
TRIM16: a context-dependent E3 ligase in autophagy, oxidative stress, and immune regulation - from cancer and systemic disease.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TRIM16 is an atypical tripartite motif (TRIM) family E3 ligase that retains catalytic activity via its RING-like B-box domains, functioning primarily as a versatile molecular scaffold. This architecture enables TRIM16 to coordinate key cellular processes. These include oxidative stress responses (via the p62-KEAP1-NRF2 axis), secretory autophagy, lysophagy, and immune regulation, which collectively maintain cellular homeostasis. Emerging evidence highlights TRIM16 as a context-dependent regulator whose functions are shaped by cell type and microenvironment. In cancer, it acts as a tumor suppressor in most solid tumors by degrading oncoproteins and inducing cell cycle arrest, yet can paradoxically promote progression in pancreatic and hepatocellular carcinomas. Beyond oncology, TRIM16 protects against neurodegenerative, cardiovascular, and inflammatory diseases through quality control mechanisms. This review integrates recent advances to elucidate TRIM16's molecular mechanisms and disease-specific functions, emphasizing its therapeutic and biomarker potential, and outlines future directions to decode its context-dependent actions for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.